Harmonette – Dragees

Harmonette dragees are a combined oral contraceptive containing the synthetic estrogen ethinylestradiol and the progestogen gestodene, supplied as oral dragees. Marketed in the European Union and available by prescription, each dragee provides a fixed dose of the two hormones. The regimen is taken once daily for 21 consecutive days followed by a 7‑day hormone‑free interval to prevent pregnancy as part of a standard hormonal birth control program.

Harmonette dragees are indicated for the prevention of pregnancy in women of reproductive age.

- Regular, once‑daily oral administration as part of a 28‑day cycle (21 active tablets, 7 placebo or hormone‑free days). - Use in women seeking a reversible, hormone‑based contraceptive method. - May be prescribed for cycle regulation when contraception is the primary goal. - Suitable for women without contraindications to estrogen‑progestogen combinations. - Can be used in conjunction with counseling on barrier methods for added protection.

Like other combined oral contraceptives, Harmonette dragees may cause a range of hormonal side effects, most of which are mild and transient.

Common: - Nausea or mild gastrointestinal discomfort. - Breast tenderness or enlargement. - Headache, including tension‑type. - Irregular menstrual bleeding or spotting, especially during the first cycles. - Mood changes such as mild irritability or emotional fluctuations. - Weight gain or fluid retention, usually modest.

Serious: - Signs of venous thromboembolism such as leg pain, swelling, or shortness of breath. - Severe allergic reaction manifested by rash, itching, swelling of the face or throat, or difficulty breathing. - Liver dysfunction signs, including jaundice, dark urine, or severe abdominal pain. - Elevated blood pressure or hypertension detected during routine monitoring.

Before prescribing Harmonette dragees, clinicians should evaluate patient history and consider several precautionary factors to minimize risks.

- History of thromboembolic disorders, such as deep‑vein thrombosis or pulmonary embolism. - Known or suspected estrogen‑dependent neoplasms, including breast or endometrial cancer. - Uncontrolled hypertension or cardiovascular disease. - Smoking in women over 35 years of age. - Liver disease that impairs hormone metabolism. - Migraines with aura or other neurological conditions that increase stroke risk. - Breastfeeding women, as hormonal contraception may affect milk production.

Harmonette dragees can interact with other medicines, altering their effectiveness or increasing the risk of adverse events.

Avoid: - Enzyme-inducing anticonvulsants such as carbamazepine, phenytoin, or rifampicin, which may reduce contraceptive efficacy. - Certain antibiotics like rifampin that increase hepatic metabolism of estrogen. - St. John’s wort, a herbal supplement known to induce CYP3A4 enzymes.

Use with caution: - Antifungal agents (e.g., ketoconazole, itraconazole) that can increase hormone levels. - Antiretroviral drugs, especially protease inhibitors, which may affect hormone concentrations. - Diuretics or antihypertensives that may influence fluid balance and blood pressure.